K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals: 8 sponsored US clinical trials, 3 recruiting.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals sponsors 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, with 1 trials.
Upper-quartile sponsor footprint
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
NCT07546500
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05128825
A Study of ZN-c3 in Patients With Ovarian Cancer
NCT04516447
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
NCT05743036
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
NCT05198804
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
NCT04833582
A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT04814108
A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
NCT04158336
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
| Phase 3 | 1 |
What is open in the K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals pipeline
3 recruiting of 8 indexed (38% open); 4 completed (50%).
Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 8 registered trials and 38% open enrollment, not the therapeutic-area sidebar.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 38% open enrollment (± trial volume)
- American Thrombosis and Hemostasis Network · 38% recruiting · 8 trials
- AskBio · 38% recruiting · 8 trials
- Athletic Greens International · 38% recruiting · 8 trials
- Banner Health · 38% recruiting · 8 trials
Related
What to do with this K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals page
8 registered trials is a research-attention snapshot, not an endorsement of K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals or any single study.
- 3 of K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer is the condition K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals pipeline card: 8 registered trials from official public datasets.Report a data error.